These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 32229597)

  • 21. Visit-to-Visit Variability of Hemoglobin A
    Ghouse J; Skov MW; Kanters JK; Lind B; Isaksen JL; Blanche P; Haunsø S; Køber L; Svendsen JH; Olesen MS; Holst AG; Gerds TA; Nielsen JB
    Diabetes Care; 2019 Jan; 42(1):134-141. PubMed ID: 30352898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visit-to-visit HbA1c variability is associated with aortic stiffness progression in participants with type 2 diabetes.
    Fang Q; Shi J; Zhang J; Peng Y; Liu C; Wei X; Hu Z; Sun L; Hong J; Gu W; Wang W; Zhang Y
    Cardiovasc Diabetol; 2023 Jul; 22(1):167. PubMed ID: 37415203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
    Hempe JM; Liu S; Myers L; McCarter RJ; Buse JB; Fonseca V
    Diabetes Care; 2015 Jun; 38(6):1067-74. PubMed ID: 25887355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study.
    Scott ES; Januszewski AS; O'Connell R; Fulcher G; Scott R; Kesaniemi A; Wu L; Colagiuri S; Keech A; Jenkins AJ
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32766757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
    Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
    Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study.
    Pei J; Wang X; Pei Z; Hu X
    Cardiovasc Diabetol; 2023 Oct; 22(1):287. PubMed ID: 37891565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.
    Basu S; Raghavan S; Wexler DJ; Berkowitz SA
    Diabetes Care; 2018 Mar; 41(3):604-612. PubMed ID: 29279299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the best predictor of mortality in patients with type 2 diabetes and chronic kidney disease: mean, variability of HbA1c or HbA1c-Hemoglobin ratio?
    Ooi SW; Lee MT; Chang YY; Chang CH; Chen HF
    BMC Nephrol; 2024 Jul; 25(1):246. PubMed ID: 39085774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study.
    Skriver MV; Støvring H; Kristensen JK; Charles M; Sandbæk A
    Diabetologia; 2012 Sep; 55(9):2361-70. PubMed ID: 22736395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study.
    Kim MK; Jeong JS; Yun JS; Kwon HS; Baek KH; Song KH; Ahn YB; Ko SH
    J Diabetes Complications; 2018 Oct; 32(10):906-910. PubMed ID: 30121206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
    Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
    Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
    Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME
    BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease.
    Kranenburg G; van der Graaf Y; van der Leeuw J; Nathoe HM; de Borst GJ; Kappelle LJ; Visseren FL; Westerink J;
    Diabetes Care; 2015 Oct; 38(10):1930-6. PubMed ID: 26307606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Salles GF
    Cardiovasc Diabetol; 2020 May; 19(1):50. PubMed ID: 32359350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between visit-to-visit variability of glycated albumin and diabetic retinopathy among patients with type 2 diabetes - A prospective cohort study.
    Dai D; Shen Y; Lu J; Wang Y; Zhu W; Bao Y; Hu G; Zhou J
    J Diabetes Complications; 2021 Sep; 35(9):107971. PubMed ID: 34187717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus.
    Rhee JJ; Zheng Y; Montez-Rath ME; Chang TI; Winkelmayer WC
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28592463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.
    Zhou JJ; Schwenke DC; Bahn G; Reaven P;
    Diabetes Care; 2018 Oct; 41(10):2187-2194. PubMed ID: 30082325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mean and visit-to-visit variability of glycemia and left ventricular diastolic dysfunction: A longitudinal analysis of 3025 adults with serial echocardiography.
    Ahn J; Koh J; Kim D; Kim G; Hur KY; Seo SW; Kim K; Kim JH; Yang JH; Jin SM
    Metabolism; 2021 Mar; 116():154451. PubMed ID: 33248066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.